ORIGINAL PAPER
The effect of omega-3 fatty acids prescription on serum levels of IL-6 and IL-1β in patients with traumatic brain injury
Submission date: 2018-08-26
Final revision date: 2018-09-06
Acceptance date: 2018-10-26
Publication date: 2018-12-31
Medical Studies 2018;34(4):276-280
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Survivors of traumatic brain injury (TBI) continue to suffer from long-term disabilities.
Aim:
To investigate the effect of omega-3 on serum levels of interleukin (IL)-1β and IL-6 in patients with traumatic brain injury.
Material and methods:
In this double-blind clinical trial study 80 patients with TBI divided into two 40-memebr groups (50 mg/kg oral omega-3 capsule group, and oral placebo capsule group). Patients took these capsules for 7 days, occurrence of leukocytosis and leukopaenia and Glasgow Coma Score (GCS) was measured. Serum levels of IL-1β and IL-6 were measured on day 7 in each of the two groups. The data were analysed using SPSS software version 20.
Results and conclusions:
There was no significant difference between basic demographic information such as age (p = 0.86), gender (p = 0.64), APACHE II (p = 0.16), and start of GCS (p = 0.36) in the two groups. On the seventh day, the mean GCS was 8.90 ±2.03 in the control group and 9.92 ±2.69 in the case group (p = 0.05), and the mean white blood cells (WBC) on the third day (p = 0.22) and seventh day (p = 0.58), mean of temperature (p = 0.21), without mechanical ventilation day (p = 0.89), and length of stay in the intensive care unit (ICU) (p = 0.27) showed no significant differences between the two groups. The serum level of IL-1β was 1154.94 ±234.31 for the control group and 2133.36 ±568.08 for the case group (p = 0.31), but the IL-6 level was 296.02 ±137.02 in the control group and 208.54 ±90.61, in the case group that showed significant differences between them (p = 0.001).
Survivors of traumatic brain injury (TBI) continue to suffer from long-term disabilities.
Aim:
To investigate the effect of omega-3 on serum levels of interleukin (IL)-1β and IL-6 in patients with traumatic brain injury.
Material and methods:
In this double-blind clinical trial study 80 patients with TBI divided into two 40-memebr groups (50 mg/kg oral omega-3 capsule group, and oral placebo capsule group). Patients took these capsules for 7 days, occurrence of leukocytosis and leukopaenia and Glasgow Coma Score (GCS) was measured. Serum levels of IL-1β and IL-6 were measured on day 7 in each of the two groups. The data were analysed using SPSS software version 20.
Results and conclusions:
There was no significant difference between basic demographic information such as age (p = 0.86), gender (p = 0.64), APACHE II (p = 0.16), and start of GCS (p = 0.36) in the two groups. On the seventh day, the mean GCS was 8.90 ±2.03 in the control group and 9.92 ±2.69 in the case group (p = 0.05), and the mean white blood cells (WBC) on the third day (p = 0.22) and seventh day (p = 0.58), mean of temperature (p = 0.21), without mechanical ventilation day (p = 0.89), and length of stay in the intensive care unit (ICU) (p = 0.27) showed no significant differences between the two groups. The serum level of IL-1β was 1154.94 ±234.31 for the control group and 2133.36 ±568.08 for the case group (p = 0.31), but the IL-6 level was 296.02 ±137.02 in the control group and 208.54 ±90.61, in the case group that showed significant differences between them (p = 0.001).
REFERENCES (21)
1.
Hukkelhoven CW, Steyerberg EW, Rampen AJ, Farace E, Habbema JD, Marshall LF, Murray GD, Maas AI. Patient age outcome following severe traumatic brain injury: an analysis of 5600 patients. J Neurosurg 2003; 99: 666-73.
2.
Narayan RK, Kishore PR, Becker DP, Ward JD, Enas GG, Greenberg RP, Domingues Da Silva A, Lipper MH, Choi SC, Mayhall CG, Lutz HA 3rd, Young HF. Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg 1982; 56: 650-9.
3.
Treggiari MM, Schutz N, Yanez ND, Romand JA. Role of intracranial pressure values and patterns in predicting outcome introunatic brain injury: a systematic review. Neurocrit Care 2007; 6: 104-12.
4.
Statler KD, Jenkins LW, Dixon CE, Clark RS, Marion DW, Kochanek PM. The simple model versus the super model: translating experimental traumatic brain injury research to the bedside. J Neurotrauma 2001; 18: 1195-206.
5.
Seltzer MB, Brooks JA. In the line of fire: traumatic brain injury among Iraq War veterans. AAOHN J 2008; 56: 347-53.
6.
Molfino A, Amabile MI, Monti M, Muscaritoli M. Omega-3 polyunsaturated fatty acids in critical illness: anti-inflammatory, proresolving, or both. Oxid Med Cell Longev 2017; 2017: 5987082.
7.
Yatsiv I, Morganti-Kossmann MC, Perez D, Dinarello CA, Novick D, Rubinstein M, Otto VI, Rancan M, Kossmann T, Redaelli CA, Trentz O, Shohami E, Stahel PF. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-blinding protein after experiment al closed had injury. J Careb Blood Flow Metab 2002; 22: 971-8.
8.
Donatello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009; 27: 519-50.
9.
Taşçi A, Okay O, Gezici AR, Ergün R, Ergüngör F. Prognostic value of interleukin-1beta levels after acute brain injury. Neurol Res 2003; 25: 871-4.
10.
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokine’s and leukocyte recruitment. Immunity 1997; 6: 315-52.
11.
Penkowa M, Camas J, Haber H. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglia degeneration induced by 6-aminoicotinamide. J Neurosis 2003; 73: 481-96.
12.
Maegele M, Sauerland S, Bouillon B, Schäfer U, Trübel H, Riess P, Neugebauer EA. Differential immunoresponses following experimental traumatic brain injury, bone fracture and “two-hit: combined neurotrauma. Inflamm Res 2007; 56: 318-23.
13.
Calder PC. Omega-3 fatty acids and inflammatory process. J Nutrients 2010; 2: 355-74.
14.
Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, Løvik M, Macfarlane S, Meyer PD, M’Rabet L, Serafini M, van Eden W, van Loo J, Vas Dias W, Vidry S, Winklhofer-Roob BM, Zhao J. Inflammatory disease processes and interaction with nutrition. Br J Nutr 2009; 101 (Suppl S1): S1-45.
15.
Elders S. n-3 polyunsaturated fatty acids and human cytokine synthesis. Lipids 1996; 31 Suppl: S239-42.
16.
Rees D, Miles EA, Banerjee T, Wells SJ, Roynette CE, Wahle KW, Calder PC. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of your and older men. Am J Clin Nutre 2006; 83: 331-42.
17.
Chen X, Wu S, Chen C, Xie B, Fang Z, Hu W, Chen J, Fu H, He H. Omega-3 polyunsaturated fatty acid supplementation the HMG-BJ/TLR4/NF-KB Pathway following experimental traumatic brain injury. J Neuroinflamm 2017; 14: 143.
18.
Zhang W, Hu X, Yang W, Gao Y, Chen J. Omega-fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory acti3 polyunsaturated on. Stroke 2010; 41: 2341-7.
19.
Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenze C, Alberti A, Di Benedetto D, Stragliotto E. Cytokine secretion and elcosanoid production in the periphery blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 1995; 56: 143-53.
20.
Hosny M, Nahas R, Ali S, Abd Elshafei S, Khaled H. Impact of oral omega-3 fatty acids supplementation in early sepsis on clinical outcome and immunomodulation. Egypt J Crit Care Med 2013; 1: 119-26.
21.
Wang D, Zhang H, Zhang Y, Li W, Sun X, Xing Y, Suo J. Effects of omega-3 polyunsaturated fatty acids on postoperative inflammatory reaction and clinical efficacy. Zhonghua Wei Chang Wai Ke Za Zhi 2015; 18: 651-5.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
